| Japanese |
|---|
| Title | 神経芽細胞腫治療後における131I-MIBGシンチグラムの意義 - 残存・再発腫瘍の生物学的活性度の判定における有用性について - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 村嶋秀市*, 竹田寛*, 奥田康之*, 中川毅*, 櫻井實** |
|---|
| Authors(kana) | |
|---|
| Organization | *三重大学医学部放射線科, **小児科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 27 |
|---|
| Number | 12 |
|---|
| Page | 1393-1400 |
|---|
| Year/Month | 1990/12 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」治療の施された神経芽細胞腫9例 (平均年齢3.5歳) を対象として計19回の131I-MIBGシンチグラフィを施行し, 残存・再発腫瘍の生物学的活性度の判定における131I-MIBGシンチグラムの有用性に関して, 尿中ドーパミン・VMA値と対比して検討を行った. CTにて, 傍脊椎部腫瘤6例, 肝転移4例の残存あるいは再発腫瘍が示された. 方法は, 131I-MIBGを7.4 - 18.5MBq (0.2 - 0.5mCi) を静注し, 48〜72時間後に, 胸腹部前面像および後面像を撮像した. 131I-MIBGシンチグラム陽性像は4例において計8回認められ, いずれも腫瘤増大傾向が強く, 尿中ドーパミン値は高値であり, 腫瘍の生物学的活性度が高いと考えられた. 陰性像を示したのは6例, 計11回で, そのうち腫瘍の増大と共に陽性化した1例を除いた5例では, 腫瘍の大きさは縮小あるいは消失し, 尿中ドーパミン値も正常で, 腫瘍の生物学的活性度は低いと考えられた. 尿中VMA値は, 131I-MIBGシンチグラムにて陽性例でも正常値を示すものがあり, 尿中ドーパミン値ほど131I-MIBGシンチグラムとの関連は強くなかった. 131I-MIBGシンチグラムは尿中ドーパミン値とともに, 神経芽細胞腫における残存・再発腫瘍の生物学的活性度の判定に有用であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 131I-MIBG, Neuroblastoma, Dopamine, VMA. |
|---|
| English |
|---|
| Title | Assessment of Biological Activity of Residual or Recurrent Tumor of Neuroblastoma with 131I-Metaiodobenzylguanidine (MIBG) Scintigraphy |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Shuichi MURASHIMA*, Kan TAKEDA*, Yasuyuki OKUDA*, Tsuyoshi NAKAGAWA*, Minoru SAKURAI** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology and **Department of Pediatrics, Mie University School of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 27 |
|---|
| Number | 12 |
|---|
| Page | 1393-1400 |
|---|
| Year/Month | 1990/12 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] 131I-Metaiodobenzylguanidine (MIBG) is now accepted as a useful agent for the diagnosis of adrenal medullary tumor. The aim of this paper is to evaluate 131I-MIBG for the assessment of the biological activity of residual or recurrent tumor after initial treatment in patients with neuroblastoma. Nineteen scans were performed for 9 patients, mean age 3.5 years-old. Computed tomography demonstrated paravertebral mass in six and metastatic liver tumor in four cases. Anterior and posterior images of the thorax and abdomen were taken 48 - 72 hours after injection of 7.4 - 18.5MBq (0.2 - 0.5mCi) 131I-MIBG. Positive images were obtained in 8 scans for four patients and followed by rapid growth of tumor and increased urinary dopamine. The biological activity of residual or recurrent tumor was thought to be high in these patients. Eleven scans for 5 patients revealed negative. In four of them, the tumor size reduced and urinary dopamine value remained within normal limits on the follow-up study. The tumor was assumed to have low biological activity in these patients. One case in which initial scan was negative became positive on the follow-up study. 131I-MIBG activity did not well correlate with urinary vanillylmandelic acid as compared with urinary dopamine. In conclusion, 131I-MIBG proved to be useful for assessing biological activity of residual or recurrent tumor of neuroblastoma and estimating the prognosis of the patient. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 131I-MIBG, Neuroblastoma, Dopamine, VMA. |
|---|